Gilead CEO Daniel O’Day Welcomes Former Colleague Dietmar Berger as New Chief Medical Officer
Appointment:
Dietmar Berger, M.D., Ph.D., has agreed to join Gilead Sciences as its new Chief Medical Officer, coming from Sanofi35.
Reunion:
This appointment reunites Gilead CEO Daniel O'Day with Berger, a key member of the oncology team from O'Day's time at Roche35.
Background:
Daniel O'Day joined Gilead in 2019 after a 30-year career at Roche and Genentech, and has led efforts to expand Gilead's focus on cancer and other life-threatening conditions24.
Recent Developments:
O'Day recently received a 5% pay raise to $22.6 million, marking his highest compensation package since joining Gilead1.
Leadership Roles:
O'Day has also assumed the role of chair of the PhRMA Board of Directors, emphasizing his commitment to advancing solutions that protect the innovation ecosystem and ensure affordable medicines4.
Sources:
1. https://www.fiercepharma.com/pharma/gileads-ceo-daniel-oday-collects-healthy-pay-raise-226m-marking-his-highest-compensation
2. https://www.gilead.com/news/news-details/2018/gilead-sciences-names-daniel-oday-chairman-and-chief-executive-officer
3. https://sfbn.org/san-francisco-biotech-news/2024/12/13/gileads-oday-relishes-berger-reunion-as-cancer-specialist-agrees-to-join-from-sanofi/
4. https://phrma.org/en/resource-center/Topics/Press-Release/Daniel-O-Day-New-Chair-of-PhRMA-Board
5. https://www.fiercebiotech.com/biotech/gileads-oday-relishes-berger-reunion-cancer-specialist-agrees-join-sanofi